Lymphoma hemophagocytic syndrome, also known as hemophagocytic lymphohistiocytosis, is characterized by the abnormal proliferation of lymphocytes and histiocytes due to a variety of pathogenic factors, accompanied by their phagocytosis of a variety of hematopoietic cells, inducing the release of a large number of cytokines, resulting in systemic hyperinflammatory response, which is life-threatening in severe cases. 1. Patients with lymphomatoid hemophagocytic syndrome usually have persistent fever, hepatosplenomegaly, hematopenia, hypertriglyceridemia and/or hypofibrinogenemia, and hemophagocytic phenomenon in bone marrow, liver, spleen and lymphatic tissues, etc.; some of the patients with central nervous system involvement will also have neurological and psychiatric symptoms, such as convulsions, epilepsy, impaired consciousness, and ataxia. 2. Lymphoma hemophagocytic syndrome progresses quickly, the condition is fierce, the mortality rate is relatively high, so the patients with clear diagnosis should be treated as early as possible, and the treatment should actively control the lymphoma, and at the same time give etoposide, dexamethasone and methotrexate etc. for induction therapy. Warm reminder: lymphoma hemophagocytic syndrome patients in the clear diagnosis, should be timely and active treatment, to avoid delaying the condition.